The U.S. Senate has confirmed Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention, giving the nation’s leading public-health agency its first permanent leader in nearly a year.
Schwartz was approved Wednesday in a 51-44 vote that largely followed party lines. Every Republican who voted supported her, while Senator Tim Kaine of Virginia was the only Democrat to join them. Five senators did not vote.
Her confirmation places her in charge of an agency confronting major infectious-disease outbreaks, workforce disruption and continuing disputes over vaccine policy under Health and Human Services Secretary Robert F. Kennedy Jr.
Schwartz, 54, becomes the 22nd director of the Atlanta-based CDC. President Donald Trump nominated her in April after two earlier choices failed to provide lasting leadership. Former Representative David Weldon’s nomination was withdrawn before his confirmation hearing, while Susan Monarez was removed less than a month after becoming CDC director following a reported disagreement with Kennedy over vaccine policy.
TRENDING TODAY
The new director arrives as health departments respond to the country’s most serious measles resurgence in decades and a large multistate cyclosporiasis outbreak linked to contaminated food.
The CDC said in an August 5 update that it was continuing to investigate domestically acquired Cyclospora infections. An earlier federal alert reported at least 1,645 confirmed cases since May, along with thousands of additional illnesses requiring further review. The parasite can cause prolonged diarrhea, stomach cramps, fatigue and dehydration.
Beyond controlling individual outbreaks, Schwartz will face the more difficult task of rebuilding confidence inside and outside the CDC.
The agency has experienced repeated leadership turnover, workforce reductions and accusations that political officials are interfering with scientific decisions. Supporters of the Trump administration argue that restructuring is necessary to make the CDC more accountable and focused on infectious diseases. Critics warn that cuts and political pressure could weaken disease surveillance, laboratory work and emergency response.
Questions about Schwartz’s ability to operate independently dominated her July confirmation hearing.
Senators repeatedly asked whether she would challenge Kennedy if he promoted vaccine policies that were not supported by scientific evidence. Schwartz told lawmakers she would “never betray the science” and said she would conduct a detailed review with CDC career specialists before accepting recommendations from federal vaccine advisers.
She did not clearly explain how she would respond if Kennedy directly ordered her to adopt a policy she believed was scientifically unsupported. Instead, she expressed confidence that the health secretary would allow her to carry out the responsibilities of CDC director.
That response initially concerned Republican Senator Bill Cassidy of Louisiana, a physician and chairman of the Senate health committee. Cassidy said the country needed a CDC leader willing to oppose statements that could weaken public confidence in immunization.
He ultimately supported Schwartz after further discussions, saying he believed she could help restore trust in the agency and address the health challenges facing Americans.
Schwartz brings an unusual combination of military, medical, legal and administrative experience.
She previously served as deputy surgeon general during Trump’s first term and as chief medical officer of the U.S. Coast Guard. In that position, she oversaw a health system that included dozens of clinics and approximately 150 sick bays, while also managing programs involving workplace safety, substance-abuse prevention, mental health and emergency preparedness.
She earned a medical degree from Brown University, a public-health degree from the Uniformed Services University and a law degree from the University of Maryland. Her background in preventive and occupational medicine could prove valuable as the CDC attempts to coordinate federal science with the practical needs of state health departments, hospitals and local communities.
However, technical qualifications alone may not be enough to stabilize the agency.
The CDC director must communicate clearly during health emergencies, protect the credibility of federal data and maintain working relationships with state officials who depend on the agency for testing, disease tracking and outbreak guidance. Schwartz will also need to convince career scientists that evidence-based recommendations will not be changed primarily for political reasons.
For ordinary families, those internal disagreements have real consequences. CDC decisions influence childhood vaccination schedules, outbreak alerts, food recalls, school guidance and the information doctors use when advising patients.
It remains uncertain how much authority Schwartz will have over vaccine policy, whether she will reverse any recent organizational changes or how she will respond publicly when her scientific assessment conflicts with Kennedy’s position.
Her first major decisions may therefore matter more than the promises made during her confirmation hearing. A transparent response to the next outbreak or vaccine dispute could begin restoring confidence. Another public leadership conflict could deepen the instability that has affected the agency for much of the past year.
Why It Matters
The CDC coordinates the national response to infectious diseases and provides information used by doctors, schools, hospitals and local governments.
Stable leadership is especially important while measles and foodborne illnesses are spreading across multiple states. Schwartz’s decisions could affect vaccination guidance, outbreak investigations and how quickly health officials warn the public about emerging threats.
Her relationship with Kennedy will also test whether scientific recommendations can remain insulated from political pressure inside the Trump administration.
What Comes Next
Schwartz is expected to be formally sworn in and take control of the CDC’s daily operations following her Senate confirmation.
Lawmakers will watch whether she fulfills her promise to rely on career scientists when reviewing vaccine and outbreak policies. Her early staffing decisions, public statements and handling of the measles and Cyclospora responses will provide the first evidence of how independently she intends to lead.
Congress may also call Schwartz back for oversight hearings if disagreements emerge between the CDC, Kennedy and federal vaccine advisers.
Congratulations to Dr. Erica Schwartz on your Senate confirmation as the next Director of @CDCgov.
Dr. Schwartz is the most qualified leader ever nominated for this role. She brings decades of experience as a physician, public health leader, and public servant committed to… https://t.co/lL2UF2lCYt
— Secretary Kennedy (@SecKennedy) August 6, 2026
